FINWIRES · TerminalLIVE
FINWIRES

加拿大皇家銀行表示,受需求擔憂影響,億滋國際短期內面臨不利局面。

-- 加拿大皇家銀行資本市場(RBC Capital Markets)週五在對億滋國際(Mondelez International,股票代碼:MDLZ)第一季業績的預覽報告中指出,該公司在已開發市場面臨挑戰,且中東衝突對需求的威脅日益加劇,導致其近期前景更為謹慎。 報告稱,由於億滋國際在中東地區直接銷售產品,其投入成本和營收均「相對容易受到」中東衝突的影響。報告指出,億滋國際可能面臨中東地區對美國產品的抵制,以及「由於能源短缺導致全球其他地區流動性下降」。 在美國,截至目前,掃描器數據顯示本季銷量成長1.6%,較上季成長約80個基點,但與兩年平均值相比下降約60個基點。 加拿大皇家銀行表示,餅乾是億滋國際最大的產品類別,約占美國銷售額的45%,但銷售量仍在下滑。報告還指出,在美國,億滋國際還面臨著來自規模較小的競爭對手的“巨大競爭壓力”,尤其是在巧克力棒領域。 加拿大皇家銀行指出,該公司營收「略低於」市場普遍預期。 同時,大宗商品成本仍然是一大挑戰,儘管該公司採取的避險策略比大多數同業更為成熟,而且隨著可可價格的下跌,億滋國際可能已經度過了最艱難的時期。 加拿大皇家銀行維持對億滋國際的「跑贏大盤」評級,目標價為63美元。

Price: $57.68, Change: $-0.04, Percent Change: -0.06%

Related Articles

Asia

National Australia Bank Shares Down After Resolution of Union Court Proceedings

National Australia Bank (ASX:NAB) shares were down about 1% in recent Monday trade following a Friday settlement with the Finance Sector Union of Australia to resolve court proceedings related to excessive additional working hours for employees.The settlement, reached on a without-admissions basis through mediation, includes the establishment of a health, safety, and well-being framework to mitigate the risks linked to working additional hours, and calls for greater oversight of such risks.The union and the bank said in a joint statement that they are "committed to continuing to work together to ensure fair and sustainable outcomes for all [National Australia Bank] employees."

$ASX:NAB
Asia

Clinuvel Pharmaceuticals Says FDA Removes Post-Authorization Requirement for Implant

Clinuvel Pharmaceuticals (ASX:CUV) said the US Food and Drug Administration (FDA) removed a requirement for a post-authorization phase one study on cardiac repolarization in relation to its Scenesse implant upon reviewing its long-term safety profile, according to a Monday filing with the Australian bourse.Scenesse is used to treat patients with erythropoietic protoporphyria, a disease that causes intolerance to light.The FDA concluded that the study was no longer needed since it would not yield valuable safety information, the filing said.

$ASX:CUV
Asia

XRF Scientific Completes Acquisition of Combustion Gas Analysis Business

XRF Scientific (ASX:XRF) has completed the acquisition of the combustion gas analysis business from Bruker AXS, according to a Monday Australian bourse filing.The company entered a binding agreement to acquire the combustion gas analysis business for $4 million upfront plus a potential $1 million earnout based on 7% of net revenue over three years, an earlier filing showed.

$ASX:XRF